SCHEMBL2925899

SCHEMBL2925899

O=C(Nc1ccc2cc(CN3CCCCC3)ccc2c1)N1CCC(c2ccc(Cl)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.75
HTR2C P28335 2/20 0.75
MAPT P10636 3/20 0.55
TP53 P04637 2/20 0.55
FAAH O00519 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
NFKB1 P19838 1/20 0.51
RAB9A P51151 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
MAPK1 P28482 1/20 0.50
CHRM4 P08173 1/20 0.50
NLRP3 Q96P20 1/20 0.50
LSS P48449 1/20 0.49
CHRM1 P11229 1/20 0.48
HTR2A P28223 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925998 0.99 MCHR1 (0.77) MCHR1HTR2CMAPTTP53FAAH
SCHEMBL6305313 0.95 MCHR1 (0.70) MCHR1HTR2CMAPTTP53FAAH
SCHEMBL6305203 0.90 MCHR1 (0.65) MCHR1HTR2CMAPTFAAHSMN1; SMN2
SCHEMBL6314243 0.90 MCHR1 (0.65) MCHR1HTR2CMAPTTP53FAAH
SCHEMBL6314150 0.90 MCHR1 (0.65) MCHR1HTR2CMAPTFAAHSMN1; SMN2
SCHEMBL6304597 0.90 MCHR1 (0.65) MCHR1HTR2CMAPTTP53FAAH
SCHEMBL2927911 0.90 MCHR1 (0.75) MCHR1HTR2CMAPTTP53FAAH
SCHEMBL2927563 0.90 MCHR1 (0.75) MCHR1HTR2CMAPTFAAHNPC1
SCHEMBL2925632 0.89 MCHR1 (0.77) MCHR1HTR2CMAPTFAAHNPC1
SCHEMBL6305166 0.89 MCHR1 (0.77) MCHR1HTR2CMAPTTP53FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885MAPT 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.